The BMS factor XIa inhibitor, milvexian (BMS-986177), is an oral antithrombotic with a Ki of 0.11 nM. A member of this macrocyclic series was previously highlighted as one of 2020’s Molecules of the Year . Poor pharmaceutic properties from previous preclinical molecules such as solubility were addressed resulting in this candidate. Milvexian [...]
< 1 minute read
Nov. 26, 2021
Milvexian: An Oral Factor XIa Inhibitor,
milvexian
selective factor Xia serine protease inhib. oral, phase II, cardiovascular from opt. of previous macrocyclic FXIa inh. Journal of Medicinal Chemistry Bristol Myers Squibb